Longeveron (LGVN) Other Accumulated Expenses (2026)
Longeveron's (LGVN) quarterly Other Accumulated Expenses came in at $341000.0 in Q1 2026.
Longeveron (LGVN) Other Accumulated Expenses (2026) Analysis & Trends
Longeveron's Other Accumulated Expenses history runs 1 years deep, the most recent figure standing at $341000.0 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Longeveron | 15.18 Bn | 15.16 Bn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 341,000.00 |